Join Taros Discovery at ELRIG Drug Discovery 2026, taking place on 14–15 October 2026 at ExCeL London, UK.
Representing Taros Discovery will be Dr. Anil Agarwal, Head of Medicinal Chemistry, meeting scientists and discovery teams working across medicinal chemistry, hit-to-lead, lead optimisation and integrated small-molecule drug discovery.
This year is also a special milestone: ELRIG Drug Discovery celebrates its 20th anniversary, while Taros marks 26 years of supporting chemistry and drug-discovery programmes. ELRIG’s 2026 programme spans medicinal chemistry, AI in compound discovery and experimental design, next-generation biophysics, multi-omics and other technologies shaping modern drug discovery.
A promising hit is only the beginning. Progressing a compound series requires continuous decisions around potency, selectivity, physicochemical properties, synthetic accessibility and developability.
Taros Discovery provides chemistry-led integrated drug discovery from hit identification through hit-to-lead, lead optimisation and candidate selection.
Our drug-discovery capabilities include:
Taros structures programmes around iterative Design–Make–Test–Analyse (DMTA) cycles, allowing experimental results and computational modelling to guide subsequent compound-design decisions.
Successful drug discovery is not simply about generating more compounds. It is about identifying which molecules are worth progressing and addressing potential liabilities before they become barriers later in development.
During hit-to-lead, Taros combines medicinal chemistry, computational chemistry and SAR studies to improve potency and selectivity while identifying early developability risks. Lead optimisation then considers multiple parameters including biological activity, physicochemical properties, metabolic stability, synthetic accessibility and other programme-specific criteria.
Key areas include:
This connected approach helps discovery teams maintain continuity between initial hit finding, follow-up chemistry and later programme development.
ELRIG Drug Discovery 2026 marks 20 years of its flagship Drug Discovery conference, with keynote sessions reflecting on two decades of progress while looking ahead to the technologies and partnerships shaping the future of pharmaceutical R&D.
For Taros Discovery, 2026 also represents 26 years of scientific experience and collaboration in chemistry and drug discovery.
Across those journeys, one question remains central:
At Taros Discovery, we believe this requires strong medicinal chemistry combined with experimental evidence, computational insight and clear scientific decision criteria.
Dr. Anil Agarwal, Head of Medicinal Chemistry, will represent Taros Discovery in London.
Meet Anil to discuss:
Whether you have an existing hit series, require additional medicinal chemistry capacity or are planning a broader integrated discovery programme, we would be pleased to discuss where Taros Discovery can support your next scientific decision.
Event: ELRIG Drug Discovery 2026
Dates: 14–15 October 2026
Venue: ExCeL London
Location: London, United Kingdom
Taros Discovery Representative: Dr. Anil Agarwal
Role: Head of Medicinal Chemistry
ELRIG describes Drug Discovery 2026 as its flagship European drug-discovery and life-sciences conference. The 2026 event marks its 20th anniversary and includes scientific tracks covering medicinal chemistry, AI in compound discovery and experimental design, next-generation biophysics, multi-omics and other emerging areas.
Taros Discovery supports medicinal chemistry programmes from hit validation and hit expansion through hit-to-lead, lead optimisation and candidate selection. Services can include compound design, synthesis, SAR exploration and multiparameter optimisation.
Yes. Taros combines medicinal chemistry, computational chemistry and SAR studies to improve potency and selectivity while identifying early developability risks and defining an appropriate optimisation strategy.
Lead optimisation considers biological activity alongside parameters such as physicochemical properties, metabolic stability, synthetic accessibility and other programme-specific developability criteria.
Computational modelling and compound prioritisation can support medicinal-chemistry design decisions, while synthesis and experimental results feed subsequent DMTA cycles.
Yes. Taros can coordinate programmes spanning hit identification, validation, medicinal chemistry, computational chemistry, hit-to-lead, lead optimisation and candidate-selection activities.
Dr. Anil Agarwal, Head of Medicinal Chemistry at Taros Discovery, will attend the conference in London.
ELRIG Drug Discovery 2026 takes place on 14–15 October 2026 at ExCeL London, UK.
The 2026 conference celebrates 20 years of ELRIG Drug Discovery, with sessions reflecting on past advances while exploring the scientific technologies and approaches expected to shape the future of drug discovery.
Taros Chemicals is a research and development partner supporting companies in performance chemicals, polymers, material science, custom synthesis and process development.
From early molecular and material concepts through route development, optimisation and scale-up, Taros combines chemistry expertise in Europe with pilot and manufacturing capabilities in India.
Our teams support partners looking to develop new materials, improve existing chemistry, investigate alternative feedstocks or translate promising laboratory chemistry into more robust and scalable processes. Get in touch with us!
ELRIG Drug Discovery 2026: Taros Discovery in London From Promising Hits Towards Development-Ready Leads Join Taros Discovery at ELRIG Drug Discovery 2026, taking place on 14–15 October 2026 at ExCeL
Renewable Materials Conference 2026: Taros Chemicals in Siegburg Performance Chemicals & Polymers – From R&D to Scale-Up Taros Discovery will attend the Renewable Materials Conference 2026 from 22–24 September in
Nordic Life Science Days 2026 : Taros Chemicals at the German Pavilion Taros will exhibit at Nordic Life Science Days (NLSDays) 2026, taking place on 8–9 September 2026 at Kistamässan
Chemspec Europe 2026: Taros Chemicals at Europe’s Leading Fine and Speciality Chemicals Exhibition Taros Chemicals will attend Chemspec Europe 2026, one of Europe’s key trade fairs for the fine and
At Taros we regularly perform contract research with an emphasis on the design and synthesis of novel building blocks, intermediates and final compounds for several applications. We pride ourselves on a 20 year track record of success in supporting diverse industries with their chemistry and innovation challenges. Our scientists specialize in organic and organometallic synthesis including polymers, from lab scale to pilot quantities. Taros operates a customer-centric and flexible business model providing our diverse clients with customized innovative discovery chemistry services:
Biotechs simply concentrate on their research and development tasks while our experienced chemists take care of all related synthetic chemistry challenges.
From new release mechanisms in band-aid material to the development of chemistry for innovative dual modes of action to help make use of new imaging techniques (PET).
Innovative display technologies require performance chemicals that allow tomorrow’s visual applications in handheld devices, car interfaces or further intelligent equipment.
Providing innovative but cost efficient early drug discovery services and technologies to our pharma customers is what drives our multidisciplinary scientists at Taros.
From literature research to pilot plant – we deliver sophisticated chemicals with full IP to our customers to help them achieve their product development goals.
Your R&D has a specific idea about how the surface should perform by modulating the coating or the curing? Get in touch with our scientists to discuss your chemistry challenge.
Great academic research often requires industrial backing and excellent synthesis capacities to bring ideas to the market – for many years we have been closing that gap.
Get in touch with us if you’d like to discuss the development of new or the improvement of existing synthetic molecules for fragrances, skin care applications or aroma molecules.
Smarter consumer goods require both improved properties and chemicals that provide an acceptable ecological footprint during their entire life cycle.
